Activated neutrophils are involved in a number of chronic inflammatory conditions, including RA and neuroinflammatory diseases, such as Alzheimer’s.
Based this in-vitro research, and on human anecdotal reports, there is evidence to support the use of APPA in other indications, all of which are in areas of high unmet need.
Diseases linked to inflammation are being investigated, including Rheumatoid Arthritis (RA). APPA has been shown to moderate several activated neutrophil functions so has the potential to be a future treatment for RA and a number of other autoimmune diseases.
AKL are also assessing the potential of APPA to favourably affect senescence, a fundamental ageing mechanism that contributes to many diseases of late life.